The therapeutic potential of psychedelics: the European regulatory perspective

被引：11

作者：

Butlen-Ducuing, Florence ^{[1
]}

McCulloch, Drummond E-Wen ^{[2
]}

Haberkamp, Marion ^{[3
]}

Mattila, Taina ^{[4
]}

Balkowiec-Iskra, Ewa ^{[5
,6
]}

Aislaitner, Georgios ^{[3
]}

Balabanov, Pavel ^{[1
]}

Lundberg, Johan ^{[7
,8
,9
]}

Stenbaek, Dea Siggaard ^{[2
,9
,10
]}

Elferink, Andre ^{[4
]}

Knudsen, Gitte M. ^{[2
,9
,11
]}

Thirstrup, Steffen ^{[1
]}

机构：

[1] European Med Agcy, NL-1083 HS Amsterdam, Netherlands

[2] Copenhagen Univ Hosp, Rigshosp, Neurobiol Res Unit, Copenhagen, Denmark

[3] Fed Inst Drugs & Med Devices, Sect Neurol, Psychiat, Ophthalmol, Bonn, Germany

[4] Med Evaluat Board Utrecht, Utrecht, Netherlands

[5] Med Univ Warsaw, Dept Expt & Clin Pharmacol, Warsaw, Poland

[6] Urzad Rejestracji Prod Leczniczych Wyrobow Med Pro, Warsaw, Poland

[7] Karolinska Inst, Ctr Psychiat Res, Dept Clin Neurosci, Stockholm, Sweden

[8] Reg Stockholm, Stockholm Hlth Care Serv, Stockholm, Sweden

[9] European Coll Neuropsychopharmacol ECNP Transnosol, Utrecht, Netherlands

[10] Univ Copenhagen, Inst Psychol, Copenhagen, Denmark

[11] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark

来源：

LANCET | 2023年 / 401卷 / 10378期

关键词：

PSILOCYBIN;

D O I：

10.1016/S0140-6736(23)00264-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：714 / 716

页数：3

共 30 条

[1] Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer
Agin-Liebes, Gabrielle, I
Malone, Tara
Yalch, Matthew M.
Mennenga, Sarah E.
Ponte, K. Linnae
Guss, Jeffrey
Bossis, Anthony P.
Grigsby, Jim
Fischer, Stacy
Ross, Stephen
[J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2020, 34 (02) : 155 - 166
[2] The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms
Barrett, Frederick S.
Bradstreet, Matthew P.
Leoutsakos, Jeannie-Marie S.
Johnson, Matthew W.
Griffiths, Roland R.
[J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2016, 30 (12) : 1279 - 1295
[3] Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder A Randomized Clinical Trial
Bogenschutz, Michael P.
Ross, Stephen
Bhatt, Snehal
Baron, Tara
Forcehimes, Alyssa A.
Laska, Eugene
Mennenga, Sarah E.
O'Donnell, Kelley
Owens, Lindsey T.
Podrebarac, Samantha
Rotrosen, John
Tonigan, J. Scott
Worth, Lindsay
[J]. JAMA PSYCHIATRY, 2022, 79 (10) : 953 - 962
[4] Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review
Breeksema, Joost J.
Kuin, Bouwe W.
Kamphuis, Jeanine
van den Brink, Wim
Vermetten, Eric
Schoevers, Robert A.
[J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2022, 36 (10) : 1100 - 1117
[5] Expectancy in placebo-controlled trials of psychedelics: if so, so what?
Butler, Matt
Jelen, Luke
Rucker, James
[J]. PSYCHOPHARMACOLOGY, 2022, 239 (10) : 3047 - 3055
[6] Psychedelics and the essential importance of context
Carhart-Harris, Robin L.
Roseman, Leor
Haijen, Eline
Erritzoe, David
Watts, Rosalind
Branchi, Igor
Kaelen, Mendel
[J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2018, 32 (07) : 725 - 731
[7] European Medicines Agency, 2023, SCI ADV PROT ASS
[8] European Medicines Agency, 2023, CLIN INV MED PROD TR
[9] European Medicines Agency, SPRAV ESK
[10] European Medicines Agency, 2023, Clinical Trials Information System (CTIS): online modular training programme

← 1 2 3 →